About us
AddBIO was founded in 2008 and has developed a solution to solve the real problem in the implant industry – weak bone. By coating any implant on the market with Zolidd, , we know that millions of patients will experience better results and faster recovery.
The landmark clinical results in the dental indication have generated serious interest from major companies. Clinical results showing significant benefit in orthopaedic indications are coming out soon, and significant interest from companies in the orthopaedic field is expected. AddBIO is pursuing a co-development and collaboration agreement with dental and orthopaedic implant partners. Zolidd is well suited for application to the implant of leading implant companies, who could benefit from differentiation and true clinical improvements.
AddBIO is a subsidiary to Accelerator Nordic AB (www.acceleratorab.se).
Clinical and scientific advisors
|
Christer Dahlin
PhD, professor
Dentist Christer Dahlin, PhD, professor - Christer has > 25 years of clinical and research experience in dentistry and implantology. He is an assistant professor at the Department of Biomaterial, University of Gothenburg, where he’s focusing on bone regeneration research. He is also working part time as a specialist in oral and maxillofacial surgery. He has a research interest in guided bone regeneration, bone substitute materials and Oral Implants.
|
Per Aspenberg
PhD, professor
Orthopaedic surgeon Per Aspenberg, PhD, professor - Per is a renowned professor and scientist with a strong reputation. His interest in drug interaction with bone led him to investigate effects of locally administered drugs. He’s a pioneer within the field and a co-founder of AddBIO. Per has published more than 250 scientific peer reviewed articles, and is a frequent guest lecturer at international meetings.
|
Orthopeadic industry expert Philip Procter, PhD, professor - Philip is an independent consultant and acting Strategic Business & Marketing Director of AddBIO. Dr. Procter has > 30 years experience working in the orthopaedic industry, in R&D, marketing, and strategic technology development.
|
|
Anders Jönsson
PhD
Orthopaedic surgeon Anders Jönsson, PhD - Anders is an experienced orthopedic surgeon, and presently head of orthopedic trauma at Sahlgrenska University Hospital in Sweden. For 7 years Anders served as a Director for Global Medical Science at Stryker Osteosynthesis, heading their activities in e.g. clinical research.
|
Pär-Olov Östman
PhD, professor
Dentist Pär-Olov Östman, PhD, professor - Pär-Olov has >17 years of clinical experience with dental implants. He runs an implantology clinic in Falun, Sweden, is a visiting professor of University of Ghent, Belgium, and is also a consultant at Biomet 3i.
|
Pentti Tengvall
PhD, professor
Biomaterials researcher Pentti Tengvall, PhD, professor - Pentti is a renowned professor with a strong reputation. For >20 years, he’s been investigating the interface between living tissue and biomaterial surfaces, and his knowledge in the area led him to develop the first prototype of Zolidd, together with professor Per Aspenberg. Pentti is a co-founder of AddBIO.
|
The Board
|
Peter Selley
Chairman
Peter Selley - Peter Selley has an extensive experience from the medical device and dental implants industry. During10 years as the CEO of Astra Tech, Peter Selley developed the business into one of the globally market leading dental implant companies. .
|
Gunilla Lundmark
CEO Pharmanest AB
Gunilla Lundmark - Gunilla is CEO of Pharmanest AB and she has more than 20 years of experience working in top management positions in the international life science industry, including Pharmacia and Q-Med, where she was previously Vice President
|
Claes Post
Claes Post, Investment Manager AlmiInvest - Claes has many years of experience from industry and academic research in pharmacology. During the last years his engagement has been focused on venture capital and Life Science start-up from universities.
|
Henrik Rammer
Thomas Gür – Thomas Gür is the CEO of Accelerator Nordic AB who is the majority shareholder of AddBIO. As a former Member of the Board of Accelerator, Thomas has overseen the spin-off of several Life Science- companies.
|
|
|